merged_ozempic-kidney-disease.txt
<question_number>1</question_number>
<answer>N/A</answer>

<question_number>2</question_number>
<answer>N/A</answer>

<question_number>3</question_number>
<answer>N/A</answer>

<question_number>4</question_number>
<answer>N/A</answer>

<question_number>5</question_number>
<answer>N/A</answer>

<question_number>6</question_number>
<answer>N/A</answer>

<question_number>7</question_number>
<answer>N/A</answer>

<question_number>8</question_number>
<answer>N/A</answer>

<question_number>9</question_number>
<answer>N/A</answer>

<question_number>10</question_number>
<answer>Gough</answer>

<question_number>11</question_number>
<answer>24 percent</answer>

<question_number>12</question_number>
<answer>inflammation reduction</answer>

<question_number>13</question_number>
<answer>semaglutide</answer>

<question_number>14</question_number>
<answer>diet and exercise modifications</answer>

<question_number>15</question_number>
<answer>40 percent</answer>

<question_number>16</question_number>
<answer>dialysis or transplant</answer>

<question_number>17</question_number>
<answer>diet and exercise modifications</answer>

<question_number>18</question_number>
<answer>cardiovascular problems</answer>

<question_number>19</question_number>
<answer>Food and Drug Administration</answer>